Stock Events

Stock Events

Mustang Bio 

$0.5988
110
+$0.03+5.05% 09:19 Today

Statistics

Day High
0.5763
Day Low
0.5763
52W High
1.85
52W Low
0.525
Volume
1,198
Avg. Volume
-
Mkt Cap
4.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-6.5
-4.38
-2.26
-0.14
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-1.92MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MBIO. It's not an investment recommendation.
Microsoft
17
MSFT
NVIDIA
17
NVDA
Apple
16
AAPL
Amazon
14
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy, directly competing in the same space as Mustang Bio.
Novartis
NVS
Mkt Cap286.78B
Novartis is a major player in CAR-T therapy with Kymriah, competing in the oncology space with Mustang Bio.
Precigen
PGEN
Mkt Cap2.18B
Precigen operates in the gene and cell therapy sector focusing on CAR-T and other cancer therapies, making it a direct competitor.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is focused on gene editing technologies, including CRISPR/Cas9, which could compete with Mustang Bio's gene therapy approaches.
Allogene Therapeutics
ALLO
Mkt Cap708.26M
Allogene Therapeutics is focused on allogeneic CAR-T therapies for cancer, competing in the same space as Mustang Bio's autologous and allogeneic therapies.

About

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Show more...
CEO
Manuel Litchman
Employees
4
Country
United States
ISIN
US62818Q3020
WKN
000A3D9TV

Listings

STU
DE
2W60.STU
XNAS
US
MBIO
BOATS
BOATS
MBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Mustang Bio stock price today?▼
The current price of MBIO is $0.60 USD — it has increased by +5.05% in the past 24 hours. Watch Mustang Bio stock price performance more closely on the chart.
What is Mustang Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Mustang Bio stocks are traded under the ticker MBIO.
Is Mustang Bio stock price growing?▼
MBIO stock has fallen by -5.85% compared to the previous week, the month change is a -9.24% fall, over the last year Mustang Bio has showed a -65.24% decrease.
What is Mustang Bio market cap?▼
Today Mustang Bio has the market capitalization of 4.32M
When is the next Mustang Bio earnings date?▼
Mustang Bio is going to release the next earnings report on November 18, 2026.
What is Mustang Bio revenue for the last year?▼
Mustang Bio revenue for the last year amounts to 0 USD.
What is Mustang Bio net income for the last year?▼
MBIO net income for the last year is -1.92M USD.
How many employees does Mustang Bio have?▼
As of August 19, 2026, the company has 4 employees.
In which sector is Mustang Bio located?▼
Mustang Bio operates in the Health & Wellness sector.
When did Mustang Bio complete a stock split?▼
The last stock split for Mustang Bio was on January 16, 2025 with a ratio of 1:50.
Where is Mustang Bio headquartered?▼
Mustang Bio is headquartered in WALTHAM, United States.